| scholarly article | Q13442814 |
| P356 | DOI | 10.1371/JOURNAL.PMED.1000335 |
| P953 | full work available at URL | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1000335&type=printable |
| https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20838656/pdf/?tool=EBI | ||
| https://europepmc.org/articles/PMC2935455 | ||
| https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20838656/?tool=EBI | ||
| http://dx.plos.org/10.1371/journal.pmed.1000335 | ||
| https://europepmc.org/articles/PMC2935455?pdf=render | ||
| P3181 | OpenCitations bibliographic resource ID | 2497986 |
| P932 | PMC publication ID | 2935455 |
| P698 | PubMed publication ID | 20838656 |
| P5875 | ResearchGate publication ID | 46256582 |
| P50 | author | Adriane Fugh-Berman | Q59684402 |
| P2860 | cites work | Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? | Q21144665 |
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation | Q28276588 | ||
| Off-label promotion, on-target sales | Q28473977 | ||
| Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study | Q29542530 | ||
| Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial | Q29615226 | ||
| Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group | Q29615228 | ||
| The pharmacokinetics and efficacy of different estrogens are not equivalent | Q32067302 | ||
| Selective estrogen receptor modulators: a controversial approach for managing postmenopausal health | Q33634978 | ||
| On the origin of great ideas: science in the age of big pharma | Q33992723 | ||
| Hormone replacement therapy in the prevention and treatment of atherosclerosis | Q34107469 | ||
| Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine | Q34165083 | ||
| Interface between authorship, industry and science in the domain of therapeutics | Q34210129 | ||
| Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention | Q34458588 | ||
| The corporate coauthor | Q34723235 | ||
| The Neurontin legacy--marketing through misinformation and manipulation | Q34917449 | ||
| Progestins and breast cancer | Q35128170 | ||
| The impact of hormones on menopausal sexuality: a literature review | Q35625760 | ||
| A comparative review of the risks and benefits of hormone replacement therapy regimens | Q35760709 | ||
| Estrogens and the skin | Q36226984 | ||
| Gynecologists and estrogen: an affair of the heart | Q36401321 | ||
| Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical | Q37388936 | ||
| Effects of estrogen with and without progestin on urinary incontinence | Q39370386 | ||
| Ethical considerations of publication planning in the pharmaceutical industry. | Q42731048 | ||
| Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study | Q43570023 | ||
| Factors associated with obstetrician-gynecologists' response to the Women's Health Initiative trial of combined hormone therapy | Q44266824 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | medical journal | Q16024164 |
| P304 | page(s) | e1000335 | |
| P577 | publication date | 2010-09-01 | |
| 2010-09-07 | |||
| P1433 | published in | PLOS MEDICINE | Q1686921 |
| P1476 | title | The haunting of medical journals: how ghostwriting sold "HRT" | |
| The Haunting of Medical Journals: How Ghostwriting Sold “HRT” | |||
| P478 | volume | 7 |
| Q47944465 | 'Forever Young'-Testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises |
| Q37718675 | Awareness and enforcement of guidelines for publishing industry-sponsored medical research among publication professionals: the Global Publication Survey |
| Q34145613 | Challenging medical ghostwriting in US courts |
| Q43409220 | Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health |
| Q35082688 | Exorcising ghostwriting…. Ghostwriting could potentially have serious repercussions for science and should therefore be treated as research misconduct |
| Q34017501 | Ghostwriting revisited: new perspectives but few solutions in sight |
| Q47738447 | Gynaecologists and industry: ain't no sunshine |
| Q24201543 | Hormone therapy in postmenopausal women and risk of endometrial hyperplasia |
| Q35047976 | How basic scientists help the pharmaceutical industry market drugs |
| Q33998699 | How industry uses the ICMJE guidelines to manipulate authorship--and how they should be revised |
| Q35004409 | How to stir up trouble…while riding a rollercoaster |
| Q24202591 | Industry sponsorship and research outcome |
| Q34403714 | Knowledge of undisclosed corporate authorship ("ghostwriting") reduces the perceived credibility of antidepressant research: a randomized vignette study with experienced nurses |
| Q33987346 | Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles |
| Q45950632 | Of conflicts, conspiracies, red herrings, and black swans. |
| Q45115564 | Of mugs, meals and more: the intricate relations between physicians and the medical industry |
| Q48014211 | On markets and morals-(re-)establishing independent decision making in healthcare |
| Q46256627 | On markets and morals--(re-)establishing independent decision making in healthcare: a reply to Joao Calinas-Correia |
| Q53115550 | Orphan papers and ghostwriting: the case against the ICMJE criterion of authorship. |
| Q38769174 | Pharmacist-industry relationships |
| Q37924431 | Prevalence of articles with honorary and ghost authors in three pharmacy journals |
| Q33851285 | Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles |
| Q56688442 | Questions over ghostwriting in drug industry |
| Q36937327 | Restoring invisible and abandoned trials: a call for people to publish the findings |
| Q36269803 | Sources of information influencing the state-of-the-science gap in hormone replacement therapy usage |
| Q53042847 | The Disposable Author: How Pharmaceutical Marketing Is Embraced within Medicine's Scholarly Literature. |
| Q36765612 | The ICMJE Recommendations and pharmaceutical marketing--strengths, weaknesses and the unsolved problem of attribution in publication ethics |
| Q34025773 | Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications |
| Q34046215 | Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation |
| Q28657906 | Who has used internal company documents for biomedical and public health research and where did they find them? |
| Q85181176 | ‘Nullius in verba’ |
Search more.